R

Retina Northwest, PC | Portland, OR

Research site

(Unclaimed)

Location

54450 SW Westgate Drive, Suite 217, Portland, Oregon, United States of America

Site insights

Top conditions

Top treatments

Bevacizumab

Ranibizumab

-Ranibizumab

APL-2

ranibizumab

Pegcetacoplan

NSAID

Elamipretide

Triamcinolone Acetonide

DHA

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 27 total trials

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (ATMOSPHERE)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling

Choroidal Neovascularization

Wet Age-related Macular Degeneration

Genetic: ABBV-RGX-314

Biological: Ranibizumab (LUCENTIS®)

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular deg...

Enrolling

Age Related Macular Degeneration (ARMD)

Drug: Elamipretide

Drug: Placebo